## **Amendments to the Claims**

## WHAT IS CLAIMED IS:

1. (Original) A compound having a formula I,

$$\begin{bmatrix} A \\ D_b \\ -X \\ D_a \end{bmatrix} = \begin{bmatrix} (R^1)_r \\ (R^2)_r \\ Q \\ R^3 \\ R^4 \end{bmatrix}$$

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

A is:

a) aryl,

- b) a 5- to 10-membered heteroaryl wherein the heteroaryl containing at least one heteroatom selected from N, O or S,
- c) C<sub>3</sub>-C<sub>8</sub> cycloalkyl,
- d) aliphatic group, or
- e) heterocyclyl,

wherein aryl, heteroaryl, cycloalkyl, heterocyclyl and aliphatic group being optionally substituted with one or more groups independently selected from R<sup>8</sup>;

D<sub>a</sub> and D<sub>b</sub> are each independently:

a bond or

 $-[C(R^c)(R^d)]_n$ , wherein  $R^c$  and  $R^d$  are each independently hydrogen,  $C_1$ - $C_6$  alkyl or aryl;

Q is:  $-C(O)OR^5$  or  $R^{5A}$ ;

X is:  $NR^6C[O]_p$ ,

 $NR^6S(O)_2$ ,

 $C[O]_p,NR^6,$ 

 $S(O)_2NR^6$  or

 $NR^7$ ;

Serial No. 10/579028

Docket No.: X-16554

Y is: a bond, CH<sub>2</sub>, S or O;

$$A \longrightarrow D_b \longrightarrow X$$
 is:

n and r are each independently: 1, 2, 3 or 4;

q is: 1, 2, 3, 4 or 5;

p is: 1 or 2;

R<sup>1</sup> and R<sup>2</sup> are each independently: hydrogen, C<sub>1</sub>–C<sub>6</sub> alkyl, halo or haloalkyl;

R<sup>3</sup> and R<sup>4</sup> are each independently:

hydrogen,

halo,

C<sub>1</sub>-C<sub>6</sub> alkyl,

C<sub>1</sub>-C<sub>6</sub> alkoxy or

aryloxy;

R<sup>3</sup> and R<sup>4</sup> are together a 3- to 6- membered carbocyclyl or heterocyclyl;

R<sup>5</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or aminoalkyl;

R<sup>5A</sup> is: carboxamide, sulfonamide, acylsulfonamide, tetrazole,

R<sup>6</sup> is each independently:

hydrogen,

 $C_1$ - $C_{12}$  alkyl,

arylalkyl,

C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or

 $(CH_2)_nC(O)$ aryl,

wherein alkyl, arylalkyl and cycloalkyl group being optionally substituted with one or more groups independently selected from R<sup>8</sup>;

R<sup>7</sup> is: hydrogen,

acyl, or

sulfonyl;

R<sup>8</sup> and R<sup>8a</sup> are each independently:

hydrogen,

 $C_1$ - $C_6$  alkyl,

 $C_1$ - $C_6$  alkoxy,

nitro,

cyano,

halo,

haloalkyl,

haloalkyloxy,

aryl,

heteroaryl,

benzyl,

aryloxy,

 $SR^9$ ,

 $S[O]_pR^9$  or

C[O]<sub>p</sub>R<sup>9</sup>; and

R<sup>9</sup> is: hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, or C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

- 2. (Original) The compound of Claim 1, wherein aryl or heteroaryl are selected from the group consisting of phenyl, naphthyl, indolyl, isoindolyl, benzoimidazolyl, quinolinyl, isoquinolinyl, pyridyl, benzothiophenyl and benzofuranyl.
- 3. (Previously Presented) The compound of Claim 2, wherein the compound is structural formula II,

$$(R^8)_q$$
 $D_b$ 
 $X$ 
 $D_a$ 
 $(R^1)_r$ 
 $Q$ 
 $R^3$ 
 $R^4$ 

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: q is 1, 2, 3, 4, or 5.

- 4. (Previously Presented) The compound of Claim 3, wherein  $R^8$  is disubstituted in 2 and 4 positions, or trisubstituted in 2, 4, and 6 positions of phenyl ring relative to  $-D_b$ -.
- 5. (Previously Presented) The compound of Claim 3, wherein the compound is structural formula III,

$$(R^8)_1 \qquad (R^8)_2 \qquad R^6 \qquad R^1 \qquad Y \qquad OH$$

$$O \qquad R^3 \qquad R^4 \qquad III$$

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: Y is: O or  $CH_2$ ;

R<sup>1</sup> is: hydrogen, halo or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>6</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

 $(R^8)_1$  and  $(R^8)_2$  are each independently: hydrogen, halo, haloalkyl or haloalkyloxy, cyano, nitro,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy or  $SR^9$ ;

R<sup>6</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and

R<sup>9</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl

6. (Previously Presented) The compound of Claim 5, wherein the compound is structural formula IV,

$$(R^8)_1 \qquad (R^8)_2 \qquad R^6 \qquad R^2 \qquad H_3C \qquad O \\ R^6 \qquad R^6 \qquad O \qquad CH_3 \qquad OH$$

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

R<sup>1</sup> and R<sup>2</sup> are each independently: hydrogen, halo or C<sub>1</sub>-C<sub>4</sub> alkyl;

 $R^{c}$ ,  $R^{d}$  and  $R^{6}$  are each independently: hydrogen or methyl; and

 $(R^8)_1$  and  $(R^8)_2$  are each independently:

hydrogen, F, Cl, Br, OMe, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>, NO<sub>2</sub>, cyano, methyl, ethyl, isobutyl, isopropyl or tert-butyl.

7. (Previously Presented) The compound of Claim 6, wherein the compound is structural formula V,

$$(R^8)_1 \qquad (R^8)_2 \qquad \qquad R^1 \qquad R^2 \qquad H_3C \qquad O \\ \qquad \qquad \qquad \qquad \qquad O \qquad \qquad CH_3 \qquad \qquad O \qquad \qquad V$$

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

R<sup>1</sup> and R<sup>2</sup> are each independently: hydrogen, methyl, ethyl or fluoro; and

 $(R^8)_1$  and  $(R^8)_2$  are each independently:

Docket No.: X-16554

hydrogen, F, Cl, Br, OMe, CF<sub>3</sub>, OCF<sub>3</sub>, SCH<sub>3</sub>, NO<sub>2</sub>, cyano, methyl, ethyl, isobutyl, isopropyl or tert-butyl.

- 8. (Canceled)
- 9. (Previously Presented) The compound of Claim 3, wherein the compound is structural formula VII,

$$R^8$$
 $R^6$ 
 $CH_3$ 
 $CH_3$ 

VII

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:  $R^1$  and  $R^2$  are each independently: hydrogen, halo or  $C_1$ - $C_4$  alkyl;

R<sup>6</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>8</sup> is: hydrogen, halo, haloalkyl or haloalkyloxy, cyano, nitro, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy or SR<sup>9</sup>; and

R<sup>9</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>3</sub>-C<sub>6</sub> cycloalkyl.

10. (Canceled)

11. (Previously Presented) The compound of Claim 1, wherein the compound is structural formula VIII,

$$(R^8)_q$$
 $R^8$ 
 $(R^1)_r$ 
 $(R^2)_r$ 
 $(R^2)_r$ 
 $(R^3)_q$ 
 $(R^3)_q$ 

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

q is 1, 2, 3 or 4; and

E is S, O or NR<sup>10</sup> wherein R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl.

12. (Previously Presented) The compound of Claim 11, wherein the compound is structural formula IX,

IΧ

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

Y is: O or CH<sub>2</sub>;

E is: S, O, NH or NCH<sub>3</sub>, NCH<sub>2</sub>CH<sub>3</sub>;

R<sup>1</sup> is: hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halo or haloalkyl;

R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup>, R<sup>6</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

 $(R^8)_1$  and  $(R^8)_2$  are each independently: hydrogen, halo, haloalkyl, haloalkyloxy, cyano, nitro,  $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkoxy; and

R<sup>8</sup> is: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl.

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Previously Presented) The compound of Claim 12, wherein the compound is structural formula XIII,

$$(R^8)_1$$

$$R^8$$

$$R^6$$

$$R^6$$

$$R^2$$

$$R^3$$

$$R^4$$

$$R^3$$

$$R^4$$

XIII

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

Y is: O or CH<sub>2</sub>;

R<sup>1</sup> is: hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, halo or haloalkyl;

R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>6</sup>, R<sup>c</sup> and R<sup>d</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>8</sup> are each independently: hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and

Docket No.: X-16554

(R<sup>8</sup>)<sub>1</sub> is: hydrogen, halo, haloalkyl or haloalkyloxy, cyano, nitroC<sub>1</sub>-C<sub>6</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> alkoxy.

- 17. (Canceled)
- 18. (Canceled)
- 19. (Canceled)
- 20. (Previously Presented) The compound of Claim 1, wherein the compound is structural formula XVI,

$$(R^8)_q \qquad R^c \qquad R^6 \qquad \qquad R^1 \qquad Y \qquad OH$$

$$(C)_n \qquad Q \qquad XVI$$

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: n is 1, 2, 3, or 4.

- 21. (Original) The compound of Claim 20, wherein Y is O or  $CH_2$ ;  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$   $R^c$  and  $R^d$  are each independently hydrogen or  $C_1$ - $C_4$  alkyl; n is 1 or 2;  $R^6$  is hydrogen,  $C_1$ - $C_6$  alkyl or arylalkyl; and  $R^8$  is hydrogen,  $C_1$ - $C_6$  alkoxy, halo or haloalkyl.
- 22. (Previously Presented) The compound of Claim 1, wherein the compound is structural formula XVII,

$$(R^{8a})_s \longrightarrow (R^{1})_r \longrightarrow (R^{2})_r \longrightarrow (R^{2})_r \longrightarrow (R^{3})_r \longrightarrow (R^$$

or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

 $R^{8a}$  is hydrogen,  $C_1$ - $C_4$  alkyl or aryl; and s is 1, 2, 3, 4, 5 or 6. 23. (Canceled)

24. (Previously Presented) The compound of Claim 1, wherein the compound having a structural formula XIX,

$$(R^8)_q \qquad (R^1)_r \qquad (R^2)_r \qquad Y \qquad Q$$
 
$$R^c \qquad R^7 \qquad R^0 \qquad R^3 \qquad R^4$$

XIX

or a pharmaceutically acceptable salt or stereoisomer thereof.

25. (Original) The compound of Claim 24, wherein Q is COOH; R<sup>7</sup> is hydrogen, mathanesulfonyl or acetyl; and R<sup>c</sup> and R<sup>d</sup> are each hydrogen.

## 26. (Previously Presented) A compound of Claim 1 selected from the group consisting of:

	Consisting of	
No	Structure	Name
1	F CI F CH <sub>3</sub> H <sub>3</sub> C O OH CH <sub>3</sub>	2-(4-{3-[(2-Chloro-4-trifluoromethyl-benzoylamino)-methyl]-5-fluoro-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid
2	CI CH <sub>3</sub> OH	3-[4-(3-{[(5-Chloro-1H-indole-2-carbonyl)-amino]-methyl}-5-fluoro-phenoxy)-2-methyl-phenyl]-propionic acid
3	F CH <sub>3</sub> F CH <sub>3</sub> CH <sub>3</sub> OH CH <sub>3</sub>	2-(4-{3-Fluoro-5-[1-(2-methyl-4-trifluoromethyl-benzoylamino)-ethyl]-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid (isomer 1)
4	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH CH <sub>3</sub> OH	2-[4-(3-{[(5-Chloro-3-methyl-benzo[b]thiophene-2-carbonyl)-amino]-methyl}-5-methyl-phenoxy]-2-methyl-propionic acid

No	Structure	Name
5	CI CH <sub>3</sub> CH <sub>3</sub> OH	(R)-3-[4-(3-{1-[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-5-fluoro-phenoxy)-2-methyl-phenyl]-propionic acid
6	F F CH <sub>3</sub> OH	3-(2-Ethyl-4-{3-fluoro-5-[(2-methyl-4-trifluoromethyl-benzoylamino)-methyl]-phenoxy}-phenyl)-propionic acid
7	F F CH <sub>3</sub> CH <sub>3</sub> O OH	2-(4-{3-[(2-Fluoro-4- trifluoromethyl-benzoylamino)- methyl]-5-methyl-phenoxy}-2- methyl-phenoxy)-2-methyl- propionic acid
8	CI CH <sub>3</sub> CH <sub>3</sub> CH <sub>3</sub> OH CH <sub>3</sub> OH	(R)-2-[4-(3-{[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-5-methyl-phenoxy)-2-methyl-propionic acid
9	F CH <sub>3</sub> OH	3-[4-(3-Fluoro-5-{[(5-fluoro-3-methyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-2-methyl-phenyl]-propionic acid
10	F CH <sub>3</sub> H <sub>3</sub> C OH  H <sub>3</sub> C OH	2-[4-(3-Fluoro-5-{[(5-fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-2-methyl-phenoxy]-2-methyl-propionic acid
11	Chiral CH <sub>3</sub> CH <sub>3</sub> OH	(R)-3-[4-(3-{1-[(5-Fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-5-methyl-phenoxy)-2-methyl-phenyl]-propionic acid

No	Structure	Name
12	F F CH <sub>3</sub> OH CH <sub>3</sub> OH	2-Methyl-2-(2-methyl-4-{3-[(2-methyl-4-trifluoromethyl-benzoylamino)-methyl]-phenoxy}-phenoxy)-propionic acid
13	F F CH <sub>3</sub> H <sub>2</sub> O OH	2-(4-{3-Fluoro-5-[(2-methyl-4-trifluoromethyl-benzoylamino)-methyl]-phenoxy}-2-methyl-phenoxy)-2-methyl-propionic acid
14	Chiral F CH <sub>3</sub> OH  CH <sub>3</sub> OCH <sub>3</sub> OH	(R)-3-[4-(3-Fluoro-5-{1-[(5-fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-ethyl}-phenoxy)-2-methyl-phenyl]-propionic acid
15	CI CH <sub>3</sub> OH	3-[4-(3-{[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-5-fluoro-phenoxy)-2-methyl-phenyl]-propionic acid
16	CI CH <sub>3</sub> OH	3-[4-(3-{[(5-Chloro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-2-methyl-phenyl]-propionic acid
17	F CH <sub>3</sub> OH	3-[2-Ethyl-4-(3-fluoro-5-{[(5-fluoro-1,3-dimethyl-1H-indole-2-carbonyl)-amino]-methyl}-phenoxy)-phenyl]-propionic acid
18	F F CI OH	3-(4-{3-[(2-Chloro-4-trifluoromethyl-benzoylamino)-methyl]-5-methyl-phenoxy}-2-ethyl-phenyl)-propionic acid

27. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1 or a pharmaceutically acceptable salt.

- 28. (Canceled)
- 29. (Canceled.)
- 30. (Canceled.)
- 31. (Canceled.)
- 32. (Canceled.)
- 33. (Canceled.)
- 34. (Canceled.)
- 35. (Canceled.)
- 36. (Canceled.)
- 37. (Canceled.)
- 38. (Canceled.)
- 39. (Previously Presented) A method for lowering blood-glucose in a mammal comprising the step of administering an effective amount of a compound of Claim 1
  - 40. (Canceled)
  - 41. (Canceled)
  - 42. (Canceled)
  - 43. (Canceled)
  - 44. (Canceled)
  - 45. (Canceled)